Atea Pharmaceuticals

• United States

Sources: sec.gov

• Founded

  Jan 1, 2013

Sources: ror.org

• Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

  Phase 1, Completed, 30 people, Jan 2, 2026

• NCT07272889

  Phase 1, Completed, 24 people, Dec 9, 2025

• Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

  Phase 1, Completed, 20 people, Jun 6, 2025

• Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

  Phase 1, Completed, 29 people, Dec 10, 2021

• Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

  Phase 1, Completed, 29 people, Nov 30, 2021

• Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

  Phase 1, Completed, 24 people, Apr 29, 2021

• Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

  Phase 1, Completed, 24 people, Apr 19, 2021

• Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

  Phase 1, Completed, 20 people, Mar 5, 2021

Sources: clinicaltrials.gov

• Series D-1

  $108M, Oct 1, 2020

• Series D

  $108K, May 1, 2020

Sources: sec.gov

• Cormorant Asset Management

  Series D-1, Oct 1, 2020

• Morningside Ventures

  Series D-1, Oct 1, 2020

• Bain Capital Life Sciences

  Series D-1, Oct 1, 2020

• Morningside Ventures

  Series D, May 1, 2020

• Bain Capital Life Sciences

  Series D, May 1, 2020

Sources: sec.gov